These BC subtypes are sensitive to endocrine-based therapy through inhibiting estradiol (E2)/ER-mediated signaling, and clinical studies have shown that endocrine therapies can considerably reduce luminal BC recurrence and mortality [5]. Here, ESR1 is linked to breast cancer.